Lannett acquires Kremers Urban Pharmaceuticals from UCB for $1.23 billion

November 27, 2015

Lannett Company, Inc. today announced that it has completed the acquisition of Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A.

Previous Article
On vaccines and autism, child pornography, and seeing “bullies” everywhere [Respectful Insolence]
On vaccines and autism, child pornography, and seeing “bullies” everywhere [Respectful Insolence]

Bullying. You keep saying that word. I do not think it means what you think it means. Yes, I do so love to ...

Next Article
Can-Fite BioPharma reports financial results, provides updates on drug development programs
Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being ...